Biotech IV Monitor

PCVX — Vaxcyte Inc.

$7.9B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Vaxcyte Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2027.

Next readoutDecember 2027in ~13 months
Upcoming readouts1none in Phase 3
Market cap$7.9B
Cash & investments$2.26B~8 quarters at last loss rate
Recent 8-K filings1latest 2026-11-04

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 31 valent pneumococcal conjugate vaccine
Pneumococcal Disease · NCT07284654
September 2026
Primary data collected

Upcoming readouts

Phase 2 0.5 mL of the low dose VAX-31
Pneumococcal Vaccines · NCT06720038
December 2027
Ongoing

Cash position

Vaxcyte Inc. reported $2.26B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-04). Its net loss for that quarter was $297M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-04

Companies working on similar indications

Discussion

No messages yet. If you follow PCVX, you can start the conversation.
Track PCVX in real time
See live implied volatility for PCVX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on PCVX
Contact — questions or corrections about PCVX: dukeupt@gmail.com